American Board of Orthodontics (ABO) Practice Exam 2026 – All-in-One Resource to Master Your Orthodontics Certification!

Denosumab is a human monoclonal antibody that specifically binds to RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand). RANKL is a crucial factor in the regulation of bone remodeling, playing a significant role in the formation and activation of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, denosumab reduces the activity of osteoclasts and thus decreases bone resorption.

In the context of orthodontics, the binding of denosumab to RANKL has implications for tooth movement and bone remodeling. While it does not directly enhance tooth movement, its effects on bone density and remodeling patterns can influence the response of the alveolar bone during orthodontic treatment. Understanding the mechanisms of denosumab allows orthodontists to consider how modulating bone metabolism could potentially improve the outcomes of orthodontic interventions.

The other options do not accurately describe the role of denosumab in orthodontics. Increased bone turnover is contrary to denosumab’s function, as it actually decreases bone turnover. Inhibiting dental caries is unrelated to the mechanism of action of denosumab. Enhancing tooth movement, while it may seem relevant, does not capture the primary action of